THE CROHN’S DISEASE 4
IntestineTransplant for the Chrohn’s disease
Intestinal transplant is the most effective healthcare treatmentoption for Chrohn’s disease. However, it is the most expensiveform of treatment. Crohn’s is an inflammatory bowel disease (IBD).It causes inflammations on the patients lining of the digestivetract. Consequently, it results in abdominal pain, fatigue, severediarrhea, malnutrition and weight loss. The inflammation can involvedifferent areas of the digestive tract for various patients.Inflammation later spreads deep into the layers of the infected boweltissues. Consequently, the disease is painful and debilitating. Itmay lead to life-threatening complications (Nickitas, 2011).
Specifically, an intestinal transplant costs USD 1,121,800. Due tothe presence of a tumor in the intestines, an operation is conductedto replace the dead intestinal tissues with living tissues obtainedfrom a donor. The high cost associated with the transplant emanatesfrom the need to perform a liver transplant. In fact, the livertransplant contributes an additional United States Dollars 180,000 tothe surgery costs (Crespi, 2009).
Besides, the high costs of the transplant emanate from the time thata patient is required to stay in the hospital. Specifically, afterthe operation, the patient requires close monitoring to detect anyform of rejection of the new tissues. Rejection is diagnosed bybiopsy. After the transplant, the body recognizes the new tissues asforeigners. Consequently, the body tries to attack the new tissues.Immunosuppressive medication is required to suppress the activity ofthe patients’ immune system and reduce the chances of tissuerejection. Although the use of the immune suppressive drugs reducesthe possibilities of tissue rejection, they weaken the patient’simmune system. The need for close monitoring also emanates from thehigh risk of the patient to contract infections (Nickitas, 2011).
A majority 85% of Crohn’s disease patients require surgery. Surgeryis effective due to its ability to maintain portions of a patient’sGI tract. Besides, after surgery, the patient recovers back to theirbest possible quality of life. The only disadvantage is thepossibility of recurrence of the disease after a long period such astwenty years (Crespi, 2009).
As an alternative, the patient can use medication that is designed tosuppress the immune systems abnormal inflammatory response. However,the use of medication is ineffective as it only reduces the typicalsymptoms such as fever, pain and diarrhea and does not serve as anoptimal solution (Nickitas, 2011).
The key strategy to advocate for legislative change to ensureinsurance coverage for the treatment is through educational mediacampaigns. Specifically, I will conduct campaigns to sensitizeinsurance companies as well as key political figures. The key messagefrom the campaign is the need for surgery to treat the disease.First, I will provide information on the available treatment optionssuch as medication and their shortcomings. Besides, I will sensitizethe insurance companies on the pain and suffering associated with thedisease (Allman, 2012).
Second, I will create the interest of the insurance companies byillustrating the low frequency of patients with the Crohn’sdisease. Consequently, the patient’s falls within the limits ofinsurable risks that call for a small spread of any given risk. Finally, I will provide education on the sources of the high costs.Specifically, I would sensitize the insurance companies on the needfor a liver transplant after the conduct of an intestine transplant.Besides, I will educate them on the need for close monitoring of thepatient to ensure recovery that necessitates their stay in thehospital all which adds up to the cost of treatment (Nickitas, 2011).
Allman,T. (2012). Crohn`sdisease.Farmington Hills, MI: Lucent Books.
Crespi,L. (2009). Diagnosticmodalities in Crohn`s disease.New York, NY: Nova Biomedical Books.
Nickitas,D. (2011). Policyand politics for nurses and other health professionals advocacy andaction (2nd ed.).Sudbury, Mass.: Jones and Bartlett.